China's 65-Drug Bulk Buy Aims to Cut Costs for 45,000 Hospitals by Year-End

For healthcare providers and policymakers, this procurement cycle is a landmark in China's drive to make essential medicines affordable. With 45,000 hospitals participating, the selection of 65 drugs directly impacts clinical practice across oncology, diabetes, and cardiovascular care. The NHSA's simultaneous rollout of quality safeguards signals that volume-driven savings will not come at the expense of drug stability or supply reliability.

China's National Healthcare Security Administration (NHSA) announced the results of its 12th nationwide centralized drug procurement round, selecting 65 essential medicines that will become available to patients at significantly reduced prices by the end of 2026. This latest cycle, held in Shanghai on July 31, attracted bids for 859 pharmaceutical products from 495 manufacturers, with 521 products from 327 companies securing winning contracts. The chosen drugs span a wide therapeutic spectrum including anti-infectives, oncology, blood clot treatments, diabetes, hypertension, hyperlipidemia, rheumatology, immunology, and pain management—reflecting the government's strategic focus on high-burden chronic and acute conditions. Since the program's inception in 2018, 12 rounds have now covered 555 medicine types, underscoring the rapid institutionalization of bulk purchasing as a core cost-containment mechanism.

“

For healthcare providers and policymakers, this procurement cycle is a landmark in China's drive to make essential medicines affordable.

The scale of this procurement is immense: 45,000 medical institutions submitted demand, making it one of the largest single-payer drug purchasing exercises in the world. The average category attracted 15 bidders, while the most competitive saw 49 companies vying for a single contract—a figure that highlights both the attractiveness of the Chinese market and the fierce price competition that drives down costs. Winning manufacturers gain volume guarantees from public hospitals, but at steep discounts; the trade-off reshapes market dynamics for both domestic and multinational generic drug producers. NHSA explicitly prioritized products with strong clinical recognition, reliable quality, and stable supply, signaling that price cuts alone do not guarantee selection.

New quality safeguards introduced in this round mark a significant regulatory evolution. Selected medicines are prohibited from altering or downgrading packaging during the procurement period, aimed at preventing stability issues that could arise from cost-cutting measures. Additionally, overseas generic manufacturers are now required to submit compliance proof meeting China's drug regulatory standards, a move that heightens entry barriers for foreign firms and may encourage local production or technology transfer. These rules address long-standing concerns about quality erosion in fiercely contested tender processes and align with a global push for supply chain resilience.

The program continues to expand its reach into grassroots healthcare delivery. NHSA encouraged broader adoption at primary care levels, meaning community health centers and rural clinics will gain access to the lower-cost drugs, improving equity. For patients with chronic diseases like diabetes and hypertension, reduced out-of-pocket costs for lifelong medications could materially improve adherence and outcomes. The inclusion of oncology drugs—often high-cost innovators or biosimilars—signals a willingness to tackle expensive specialty therapies, though the precise molecules remain undisclosed at this preliminary stage.